Metabolism and excretion of a new antianxiety drug candidate, CP- 93,393, in cynomolgus monkeys: Identification of the novel pyrimidine ring cleaved metabolites

Drug Metabolism and Disposition

Volumn 25, Issue 12, 1997, Pages 1395-1406

  Prakash, Chandra ^a   Cui, Donghui ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 PYRIMIDIN 2 YL OCTAHYDROPYRIDO[1,2 A] PYRAZIN 7 YL METHYL)PYRROLIDINE 2,5 DIONE; ANXIOLYTIC AGENT; BETA GLUCURONIDASE; DRUG METABOLITE; GLUCURONIC ACID; PYRIMIDINE DERIVATIVE; SUCCINIMIDE; SULFATASE; SULFURIC ACID; SUNEPITRON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DERIVATIZATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG EXCRETION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; HYDROXYLATION; MALE; MASS SPECTROMETRY; METHYLATION; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; OXIDATION; PRIORITY JOURNAL;

ANIMALS; ANTI-ANXIETY AGENTS; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; FEMALE; MACACA FASCICULARIS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; PYRAZINES; PYRIMIDINES; RECEPTORS, ADRENERGIC, ALPHA-2; SEROTONIN AGONISTS; SUCCINIMIDES;

EID: 0345310074     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. A. W. Schmidt, C. B. Fox, J. Lazzaro, S. McLean, A. Ganong, D. W. Schulz, K. Desai, G. M. Bright, and J. Heym: CP-93,393, a novel anxiolytic-antidepressant agent with both 5-HT1A agonist and alpha-2 adrenergic properties: in vitro studies. Neurosci. Abstr. 21, 2106 (1995).
2. L. S. Reynolds, J. P. Braselton, J. S. Sprouse, H. Rollema, T. Clarke, S. McLean, W. Horner, and J. Heym: In vivo profile of CP-93,393: evidence of combined 5-HT1A agonist and alpha-2 adrenergic antagonist activities. Neurosci. Abstr. 21, 2106 (1995).
3. P. A. Seymour, K. Desai, and G. M. Bright: Anxiolytic activity of CP-93,393: enhanced efficacy via combined 5-HT1A agonist and alpha-2 adrenergic antagonist activities. Neurosci. Abstr. 21, 2106 (1995).
4. A. W. Schmidt, C. B. Fox, E. R. Jackson, J. Lazzaro, S. McLean, A. Ganong, S. H. Zorn, D. W. Schulz, K. Desai, G. M. Bright, and J. Heym: CP-93,393, in vitro characterization of a novel anxiolytic/antidepressant agent with both 5-HT1A agonist and alpha-2 adrenergic properties. J. Neurochem. 66(Suppl. 2), S-38 (1996).
5. W. P. Weisenburger, C. L. Kozak, L. A. Medeiros, and D. S. Chapman: Evaluation of a new anxiolytic and antidepressant, CP-93, 393: pre- and post natal study in rats. Teratology 53, 123 (1996).
6. H. Rollema, T. Clarke, Y. Lu, A. W. Schmidt, and J. S. Sprouse: Comparison of the effects of CP-93,393 and buspirone on 5HT and NE release: microdialysis studies in the hippocampus of freely moving rat and guinea pig. J. Neurochem. 66(Suppl. 2), S-37 (1996).
7. C. Prakash and V. Soliman: Metabolism and excretion of a novel anti-anxiety drug candidate. CP-93,393 in Long Evans rats: differentiation of regioisomeric glucuronides by LC/MS/MS and LC/MS/MS/MS. Drug Metab. Dispos. 25, 1288-1297 (1997).
8. E. L. Luther, M. J. Cole, V. Soliman, J. G. Baxter, and H. G. Fouda: HPLC/RAM/ESI/MS/MS studies on the metabolic fate of the anxiolytic agent CP-93,393. In "Proceedings of the 44th American Society of Mass Spectrometry Conference on Mass Spectrometry and Allied Topics," Portland, OR (Abstr.), p. 250, 1996.
9. T. Poll, A. F. Abdel Hady, R. Karge, G. Linz, J. Weetman, and G. Helmchen: N-substituted hydroxysuccinimide from (S) malic acid as a new reagents for asymmetric Diels-Alder additions to enoates. Tetrahedron Lett. 30, 5595-5598 (1989).
10. H. Shih and G. O. Rankin: Convenient synthesis of N-aryl-2-hydroxysuccinimides and characterization of their hydrolysis products. Synthesis 866-867 (1989).
11. M. J. Avery and H. G. Fouda: Quantitative determination of CP-93,393 in serum at trace levels by HPLC/MS/MS. In "Proceedings of the 44th American Society of Mass Spectrometry Conference on Mass Spectrometry and Allied Topics," Portland, OR (Abstr.), p. 1311, 1996.
12. M. Rowland and T. N. Tozer: In "Clinical Pharmacokinetic Concepts and Applications," 2nd ed. Lea and Febiger, Philadelphia, 1989.
13. S. L. Malcolm and T. R. Marten: Determination of debrisoquine and its 4-hydroxy metabolite in plasma by gas chromatography/mass spectrometry. Anal. Chem. 48, 807-809 (1976).
14. D. J. Tweedie and M. D. Burke: Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism of the beta-carbolines harmine and harmol. Biochem. Pharmacol. 32, 653-63 (1983).
15. P. K. Smith, R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk: Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85 (1985).
16. T. Omura and R. Sato: The carbon monoxide binding pigment of liver microsomes: I. Evidence of its hemoprotein nature. J. Biol Chem. 239, 2370-78 (1964).
17. 3H labeled ziprasidone. Drug Metab. Dispos. 25, 212-218 (1997).
18. C. Prakash, A Kamel, J. Gummerus, and K. Wilner: Metabolism and excretion of the antipsychotic drug ziprasidone in human. Drug Metab. Dispos. 25, 863-872 (1997).
19. H. K. Jajoo, R. F. Mayol, J. A. Labudde, and I. A. Blair: Metabolism of the antianxiety drug buspirone in the rat. Drug Metab. Dispos. 17, 625-633 (1989).
20. H. K. Jajoo, R. F. Mayol, J. A. Labudde, and I. A. Blair: Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab. Dispos. 17, 634-640 (1989).
21. Y. Mizuno, K. Matoba, I. Nakatsuka, and A. Yoshtake: Metabolism of SM-3997. Clin. Rep. 26, 209-225 (1992).
22. M. A. Shamat: The role of gastrointestinal microflora in the metabolism of drugs. Int. J. Pharmaceut. 97, 1-13 (1993).
23. P. Koch, D. R. Hirst, and B. R. Wartburg: Biological fate of sirdalud in animals and man. Xenobiotica 19, 1255-1265 (1989).
24. M. Fujimaki, N. Ishigaki, and H. Hakusui: Metabolic fate of the oral hypoglycaemic agent, midaglizole, in rats. Xenobiotica 19, 609-625 (1989).
25. M. Chang, V. K. Sood, G. J. Wilson, D. A. Kloosterman, P. E. Sanders, M. J. Hauer, and P. E. Fagerness: Metabolism of the human immunodefficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats. Drug Metab. Dispos. 25, 228-242 (1997).
26. A. Enreille, J. F. Pognat, M. J.Galmier, C. Lartigue-Mattei, J. L. Chabard, N. Busch, and J. A. Berger: N-Dephenylated and N-phenyl urinary metabolites of mociprazine (CERM 3517) in beagle dogs after oral administration: a mass spectrometric determination. Eur. J. Drug Metab. Pharmacokinet. 16, 161-172 (1991).
27. T. Ohe, T. Mashino, and M. Hirobe: Novel metabolic pathway of arylethers by cytochrome P450: cleavage of the oxygen-aromatic ring bond accompanying ipso-substitution by the oxygen atom of the active species in cytochrome P450 models and cytochrome P450. Archiv. Biochem. Biophy. 310, 402-409 (1994).
28. Y. C. Chui, B. Esaw, and B. Laviolette: Investigation of the metabolism of azaperone in the horse. J. Chromatogr. 652, 23-33 (1994).
29. A. Gescher, M. D'Incalci, R. Fanelli, and P. Ferina: N-Hydroxymethylpentamethylmelamine, a major in vitro metabolite of hexamethylmelamine. Life Sci. (Washington, D.C.) 26, 147-154 (1980).
30. G. Huizing, J. Segura, and A. H. Beckett: On the mechanism of metabolic N-dealkylation. Isolation of relatively stable carbinolamine. J. Pharm. Pharmacol. 32, 650-651 (1980).
31. N. Lander, A. H. Soloway, J. P. Minton, B. D. Rawal, and C. C. Gairola: Potential metabolite mutagens of caffeine and various methylxanthines. J. Pharm. Sci. 77, 955-958 (1988).